At PCMG Clinical Outsourcing Community today, Ali Pashazadeh, Treehill Partners CEO, was giving a podium presentation on “A view from the top – how will Clinical Development Outsourcing adapt to a rapidly changing landscape”. The session focused on how to bridge the capabilities gap at biotech, for the pharma industry as a whole to continue existing – quite a fundamental challenge. We are grateful for the discussions around the event and look forward to working with companies on making a change. In terms of summary of the session, we could not have said it any better:
https://www.linkedin.com/feed/update/urn:li:activity:7340339368638734340:
“’We don’t have a funding problem. We have a capability problem.’
And he’s right.
In an industry obsessed with capital scarcity, the real drought is one of executional readiness.
Most early-stage biotechs don’t fail because the science is weak.
They fail because studies are misaligned. Protocols are outdated.
CROs aren’t challenging assumptions.
And there’s no clear path to commercial relevance.
Ali’s presentation didn’t just describe the problem, it challenged the audience to own it:
• 70% of biotechs are unfundable due to operational and strategic gaps.
• CROs must stop being order takers and start being strategic co-pilots.
• Biotechs must stop designing for KOLs and start designing for the market.
• Investors aren’t solving your funding crisis—they’re solving for returns.
So, what if we stop waiting for the capital to return… and start earning it back?”